Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System

Inclusion Criteria: * ≥ 18 years old * DOAC administered for a minimum of 7 days Exclusion Criteria: * Genetic Bleeding disorders. Known or subsequently discovered inherited defects of coagulation (e.g. hemophilia or Von Willebrand disease) * Not known when last two DOAC doses were administered prior to blood draw * DOAC first administered (or resumed after temporary cessation) less than 7 days prior to blood draw * DOAC dosage outside of manufacturer's recommended range (e.g. study subject with renal impairment and supratherapeutic dose) * Heparin or LMWH administered within 7 days prior to blood draw * On any medications known to affect coagulation status and listed below * Bruising, wounds or scarring in the area of venipuncture List of medications known to affect coagulation status 1. Vitamin K Antagonists \[VKAs\] Warfarin Phenprocoumon Acenocoumarol Tecarfarin \[ATI-5923\] Phenindione Anisindione Elinogrel Vorapaxar Atopaxar 2. Heparin and Heparins Unfractionated Heparin \[UFH\] LMWH Fondaparinux Idraparinux Danaparoid 3. Vasopressin Analogues DDAVP 4. Direct Thrombin \[IIa\] Inhibitors Hirudin Lepirudin Bivalirudin Argatroban 5. Defibrinating Agents Ancrod